-
Je něco špatně v tomto záznamu ?
The Salutary Effects of Diminazene, Lisinopril or Valsartan on Cisplatin - Induced Acute Kidney Injury in Rats: A Comparative Study
YM. Al Suleimani, BH. Ali, H. Ali, P. Manoj, KS. Almashaiki, AM. Abdelrahman
Status minimální Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, srovnávací studie
NLK
Directory of Open Access Journals
od 1991
Free Medical Journals
od 1998
PubMed Central
od 2020
ProQuest Central
od 2005-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Nursing & Allied Health Database (ProQuest)
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1998
- MeSH
- akutní poškození ledvin * chemicky indukované patologie metabolismus prevence a kontrola farmakoterapie MeSH
- cisplatina * toxicita MeSH
- diminazen * analogy a deriváty farmakologie terapeutické užití MeSH
- inhibitory ACE farmakologie MeSH
- krysa rodu rattus MeSH
- ledviny účinky léků patologie metabolismus MeSH
- lisinopril * farmakologie MeSH
- potkani Wistar * MeSH
- protinádorové látky toxicita MeSH
- valsartan * farmakologie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
Nephrotoxicity as a cause of acute kidney injury (AKI) induced by cisplatin (CP), limits its usefulness as an anticancer agent. Diminazene, an angiotensin converting enzyme 2 activator, exhibited renoprotective properties on rat models of kidney diseases. This research aims to investigate the salutary effect of diminazene in comparison with lisinopril or valsartan in CP-induced AKI. The first and second groups of rats received oral vehicle (distilled water) for 9 days, and saline injection or intraperitoneal CP (6 mg/kg) on day 6, respectively. Third, fourth, and fifth groups received intraperitoneal injections of CP on day 6 and diminazene (15 mg/kg/day, orally), lisinopril (10 mg/kg/day, orally), or valsartan (30 mg/kg/day, orally), for 9 days, respectively. 24h after the last day of treatment, blood and kidneys were removed under anesthesia for biochemical and histopathological examination. Urine during the last 24 h before sacrificing the rats was also collected. CP significantly increased plasma urea, creatinine, neutrophil gelatinase-associated lipocalin, calcium, phosphorus, and uric acid. It also increased urinary albumin/creatinine ratio, N-Acetyl-beta-D-Glucosaminidase/creatinine ratio, and reduced creatinine clearance, as well the plasma concentrations of inflammatory cytokines [plasma tumor necrosis factor-alpha, and interleukin-1beta], and significantly reduced antioxidant indices [catalase, glutathione reductase , and superoxide dismutase]. Histopathologically, CP treatment caused necrosis of renal tubules, tubular casts, shrunken glomeruli, and increased renal fibrosis. Diminazine, lisinopril, and valsartan ameliorated CP-induced biochemical and histopathological changes to a similar extent. The salutary effect of the three drugs used is, at least partially, due to their anti-inflammatory and antioxidant effects. Keywords: Cisplatin, Diminazene, ACE2 activator, Lisinopril, Valsartan, Acute kidney injury.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24009823
- 003
- CZ-PrNML
- 005
- 20250312151332.0
- 007
- ta
- 008
- 240606s2024 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.935210 $2 doi
- 035 __
- $a (PubMed)38710058
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Al Suleimani, Y M $u Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Al Khod, Oman, yousufm@squ.edu.om
- 245 14
- $a The Salutary Effects of Diminazene, Lisinopril or Valsartan on Cisplatin - Induced Acute Kidney Injury in Rats: A Comparative Study / $c YM. Al Suleimani, BH. Ali, H. Ali, P. Manoj, KS. Almashaiki, AM. Abdelrahman
- 520 9_
- $a Nephrotoxicity as a cause of acute kidney injury (AKI) induced by cisplatin (CP), limits its usefulness as an anticancer agent. Diminazene, an angiotensin converting enzyme 2 activator, exhibited renoprotective properties on rat models of kidney diseases. This research aims to investigate the salutary effect of diminazene in comparison with lisinopril or valsartan in CP-induced AKI. The first and second groups of rats received oral vehicle (distilled water) for 9 days, and saline injection or intraperitoneal CP (6 mg/kg) on day 6, respectively. Third, fourth, and fifth groups received intraperitoneal injections of CP on day 6 and diminazene (15 mg/kg/day, orally), lisinopril (10 mg/kg/day, orally), or valsartan (30 mg/kg/day, orally), for 9 days, respectively. 24h after the last day of treatment, blood and kidneys were removed under anesthesia for biochemical and histopathological examination. Urine during the last 24 h before sacrificing the rats was also collected. CP significantly increased plasma urea, creatinine, neutrophil gelatinase-associated lipocalin, calcium, phosphorus, and uric acid. It also increased urinary albumin/creatinine ratio, N-Acetyl-beta-D-Glucosaminidase/creatinine ratio, and reduced creatinine clearance, as well the plasma concentrations of inflammatory cytokines [plasma tumor necrosis factor-alpha, and interleukin-1beta], and significantly reduced antioxidant indices [catalase, glutathione reductase , and superoxide dismutase]. Histopathologically, CP treatment caused necrosis of renal tubules, tubular casts, shrunken glomeruli, and increased renal fibrosis. Diminazine, lisinopril, and valsartan ameliorated CP-induced biochemical and histopathological changes to a similar extent. The salutary effect of the three drugs used is, at least partially, due to their anti-inflammatory and antioxidant effects. Keywords: Cisplatin, Diminazene, ACE2 activator, Lisinopril, Valsartan, Acute kidney injury.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a akutní poškození ledvin $x chemicky indukované $x patologie $x metabolismus $x prevence a kontrola $x farmakoterapie $7 D058186
- 650 12
- $a lisinopril $x farmakologie $7 D017706
- 650 12
- $a cisplatina $x toxicita $7 D002945
- 650 12
- $a valsartan $x farmakologie $7 D000068756
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a diminazen $x analogy a deriváty $x farmakologie $x terapeutické užití $7 D004133
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 12
- $a potkani Wistar $7 D017208
- 650 _2
- $a protinádorové látky $x toxicita $7 D000970
- 650 _2
- $a inhibitory ACE $x farmakologie $7 D000806
- 650 _2
- $a ledviny $x účinky léků $x patologie $x metabolismus $7 D007668
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Ali, B H
- 700 1_
- $a Ali, H
- 700 1_
- $a Manoj, P
- 700 1_
- $a Almashaiki, K S
- 700 1_
- $a Abdelrahman, A M
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 73, č. 2 (2024), s. 227-237
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38710058 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y - $z 0
- 990 __
- $a 20240606 $b ABA008
- 991 __
- $a 20250312151338 $b ABA008
- 999 __
- $a min $b bmc $g 2283486 $s 1219653
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 73 $c 2 $d 227-237 $e 20240430 $i 1802-9973 $m Physiological research $n Physiol Res $x MED00003824
- LZP __
- $a Pubmed-20240606